Internal Medicine, Pulmonary Disease · Johnston, RI
NPI
1417063603
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
1524 Atwood Ave Ste 220
Johnston, RI, 02919
Phone (401) 272-1900
Groups this clinician bills Medicare through
Medicare paid, 2024
$92K
1,355 services
Medicare patients, 2024
419
Average age 77
Drug cost, 2024
$1.4M
6,052 prescriptions
Company payments, 2025
$2,614
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raffi Calikyan was code 99232 (hospital e&m - subsequent), 443 times for 125 patients. In total Raffi Calikyan billed 1,355 services in 28 codes, and Medicare paid $92K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-23.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 443 | 125 | $58.32 | $26K |
| 99213 Office E&M - Established | Office | 301 | 217 | $64.15 | $19K |
| 99238 Hospital Discharge Management | Facility | 130 | 111 | $60.53 | $7,869 |
| 94010 Pulmonary Function Testing | Office | 118 | 117 | $19.41 | $2,291 |
| 99233 Hospital E&M - Subsequent | Facility | 77 | 34 | $87.92 | $6,770 |
| 99291 Critical Care E&M | Facility | 72 | 14 | $158.17 | $11K |
| 99223 Hospital E&M - Initial | Facility | 54 | 54 | $128.39 | $6,933 |
| 99231 Hospital E&M - Subsequent | Facility | 44 | 18 | $36.93 | $1,625 |
| 99222 Hospital E&M - Initial | Facility | 30 | 27 | $94.43 | $2,833 |
| 99203 Office E&M - New | Office | 28 | 28 | $75.31 | $2,109 |
| 99214 Office E&M - Established | Office | 14 | 14 | $97.61 | $1,367 |
By year: 2022 $116K for 1,737 services; 2023 $96K for 1,439 services; 2024 $92K for 1,355 services.
Medicare prescription drug claims, 2024
In 2024, the drug Raffi Calikyan prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 663 prescriptions and refills. In total Raffi Calikyan wrote 6,052 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 663 | 771 | 118 | $491K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 567 | 616 | 158 | $16K |
| Ventolin Hfa Albuterol Sulfate | 225 | 231 | 69 | $12K |
| Breo Ellipta Fluticasone/Vilanterol | 222 | 289 | 36 | $113K |
| Montelukast Sodium Generic | 210 | 495 | 50 | $3,042 |
| Prednisone Generic | 198 | 203 | 102 | $904 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 172 | 204 | 39 | $13K |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 169 | 179 | 25 | $80K |
| Furosemide Generic | 158 | 356 | 47 | $1,066 |
| Atorvastatin Calcium Generic | 144 | 388 | 44 | $1,358 |
| Fluticasone Propionate Generic | 136 | 290 | 55 | $2,760 |
| Gabapentin Generic | 109 | 178 | 25 | $1,481 |
| Amlodipine Besylate Generic | 100 | 271 | 27 | $813 |
| Omeprazole Generic | 88 | 253 | 27 | $1,471 |
| Spiriva Respimat Tiotropium Bromide | 87 | 112 | 31 | $55K |
Brand drugs: - claims; generic drugs: 3,641 claims; opioid claims: 79.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raffi Calikyan $2,614 ($2,614 in general payments such as food, travel and fees) from 29 companies. The largest payer was GlaxoSmithKline, LLC. with $560.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 27 | $560 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $228 |
| Genzyme Corporation SNY | 6 | $209 |
| Grifols USA, LLC | 8 | $168 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $152 |
| Verona Pharma, Inc. VRNA | 7 | $145 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $136 |
| Abbvie Inc. ABBV | 4 | $98.88 |
| Actelion Pharmaceuticals US, Inc. JNJ | 3 | $92.22 |
| Phathom Pharmaceuticals, Inc. PHAT | 4 | $88.91 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.